Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma

J. Kovacova, A. Poprach, T. Buchler, WC. Cho, O. Slaby,

. 2018 ; 56 (9) : 1426-1431. [pub] 20180828

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028571

Grantová podpora
NV15-34678A MZ0 CEP - Centrální evidence projektů

Renal cell carcinoma (RCC) accounts for 2%-3% of all malignant tumours. The first-choice treatment in metastatic RCC (mRCC) patients is tyrosine kinase inhibitors (TKIs). Although TKIs may prolong survival of the treated patients who are not primary resistant, almost all of them will eventually develop secondary resistance to the treatment after a progression-free period. To predict treatment response, thus, we need efficient biomarkers for rational indication of TKIs in mRCC. MicroRNAs (miRNAs) not only play important roles in the pathogenesis of many cancers, including RCC but also have been shown to serve as promising diagnostic, prognostic and predictive biomarkers in various cancers. However, the potential of miRNAs to predict response to therapy with TKIs in mRCC has not yet gained sufficient attention. Because personalisation of the TKIs indication in mRCC presents an important unmet medical need, we summarise research on this topic and give an overall insight on the current knowledge in this field.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028571
003      
CZ-PrNML
005      
20201116155503.0
007      
ta
008      
190813s2018 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1515/cclm-2017-0861 $2 doi
035    __
$a (PubMed)29451857
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Kovacova, Julia $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
245    10
$a MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma / $c J. Kovacova, A. Poprach, T. Buchler, WC. Cho, O. Slaby,
520    9_
$a Renal cell carcinoma (RCC) accounts for 2%-3% of all malignant tumours. The first-choice treatment in metastatic RCC (mRCC) patients is tyrosine kinase inhibitors (TKIs). Although TKIs may prolong survival of the treated patients who are not primary resistant, almost all of them will eventually develop secondary resistance to the treatment after a progression-free period. To predict treatment response, thus, we need efficient biomarkers for rational indication of TKIs in mRCC. MicroRNAs (miRNAs) not only play important roles in the pathogenesis of many cancers, including RCC but also have been shown to serve as promising diagnostic, prognostic and predictive biomarkers in various cancers. However, the potential of miRNAs to predict response to therapy with TKIs in mRCC has not yet gained sufficient attention. Because personalisation of the TKIs indication in mRCC presents an important unmet medical need, we summarise research on this topic and give an overall insight on the current knowledge in this field.
650    _2
$a inhibitory angiogeneze $x terapeutické užití $7 D020533
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x genetika $x patologie $7 D002292
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x farmakoterapie $x genetika $x patologie $7 D007680
650    _2
$a mikro RNA $x metabolismus $7 D035683
650    _2
$a prognóza $7 D011379
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    _2
$a sunitinib $x terapeutické užití $7 D000077210
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Buchler, Tomas $u Department of Oncology, Thomayer Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Cho, William C $u Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong.
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
773    0_
$w MED00010886 $t Clinical chemistry and laboratory medicine $x 1437-4331 $g Roč. 56, č. 9 (2018), s. 1426-1431
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29451857 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20201116155501 $b ABA008
999    __
$a ok $b bmc $g 1433720 $s 1067031
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 56 $c 9 $d 1426-1431 $e 20180828 $i 1437-4331 $m Clinical chemistry and laboratory medicine $n Clin Chem Lab Med $x MED00010886
GRA    __
$a NV15-34678A $p MZ0
LZP    __
$a Pubmed-20190813
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace